Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06347731 | Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) | completed | N/A | 47 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06062901 | An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors | completed | N/A | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | completed | Phase 1 | 168 | AbbVieINDUSTRY | 10 | Dec 10, 2025 | clinicaltrials |
| NCT05417750 | A Phase I Study of GC101 TIL in Advanced Solid Tumors(MIZAR-001) | completed | Phase 1 | 43 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05790538 | Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN ) | completed | — | 200 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05105971 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China | completed | Phase 1 | 30 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05155722 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors | completed | Phase 1 | 59 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04021043 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04620369 | Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy | completed | Phase 3 | 106 | Mayo ClinicOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04826458 | Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology | completed | N/A | 124 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05134948 | A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors(RELATIVITY 059) | completed | Phase 1 / Phase 2 | 24 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT06001580 | A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors | completed | Phase 1 | 15 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03486301 | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab(EIK1001) | completed | Phase 1 | 87 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03911557 | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | completed | Phase 2 | 14 | John L. Villano, MD, PhDOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04196530 | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab(EIK1001) | completed | Phase 1 | 40 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04819373 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | completed | Phase 2 | 1 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04840394 | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 1 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT05322408 | HCW9218 in Select Advanced Solid Tumors | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05847686 | Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | completed | Phase 1 / Phase 2 | 55 | University of WashingtonOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT05018208 | Remote Monitoring in Cancer Care: A Platform Study | completed | — | 100 | Mayo ClinicOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03010176 | Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | completed | Phase 1 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 29, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06322615 | Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy | completed | N/A | 30 | Mayo ClinicOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06030427 | Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors | completed | N/A | 19 | Mayo ClinicOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02680795 | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | completed | Phase 1 | 17 | Acrotech Biopharma Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04010240 | A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study(NTRK) | completed | — | 3,820 | Institut BergoniéOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | completed | Phase 1 | 135 | Prelude TherapeuticsINDUSTRY | 5 | Oct 16, 2025 | clinicaltrials |
| NCT02512926 | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children(POE14-01) | completed | Phase 1 | 4 | Stanford UniversityOTHER | 2 | Oct 15, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06644170 | A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | completed | Phase 1 | 15 | University of WashingtonOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03892967 | Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial | completed | N/A | 50,207 | Mayo ClinicOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT04362748 | Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | completed | Phase 1 | 34 | AmgenINDUSTRY | 4 | Oct 7, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06296056 | Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)(SDH-Combi) | completed | Phase 1 | 9 | Seoul HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01239381 | Individualized Stereotactic Body Radiotherapy of Liver Metastases | completed | N/A | 92 | Massachusetts General HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03493945 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | completed | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04319198 | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | completed | Phase 4 | 25 | Gilead SciencesINDUSTRY | 3 | Sep 30, 2025 | clinicaltrials |
| NCT04810052 | Positive Activities Intervention to Improve Quality of Life in Collectivist Culture Cancer Patients and Their Caregivers | completed | N/A | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2025source: clinicaltrials